Prospective randomised controlled trial to investigate the effectiveness of inhalers for the relief of breathlessness in patients with lung cancer and COPD - Airway disease optimisation of pharmaco-therapy in lung cancer

Royal Marsden Hospital0 个研究点目标入组 65 人开始时间: 2010年10月8日最近更新: 2020年7月27日

适应症

试验速览

暂无简介。

•1.Male or female, age > 35 years
•2.Diagnosis of lung cancer ( Non-small cell lung cancer, Small cell lung cancer and mesothelioma)
•3.Diagnosis of chronic obstructive pulmonary disease (COPD)
•4.Subjective dyspnoea (breathlessness) of VAS score >/= 4
•Are the trial subjects under 18?
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years)
•F.1.3.1 Number of subjects for this age range

•1.Involvement in any other studies of breathlessness
•2.Reversible causes of breathlessness
•3.Patients receiving radiotherapy, chemotherapy, biological therapy or surgery. Or with a plan to commence these treatments within 4 weeks
•4.Current use of bronchodilators either inhaled or oral (aminophyline, methyxanthines) except for short-acting bronchodilators
•5.Recent change to oral corticosteroid therapy dose (within 1 week of randomisation)
•6.Current use of beta-blockers for any reason
•7.Current use of anti-cholinergic containing drugs
•8.Current use of potent CYP30 inhibitors (ritonavir, ketoconazole, itraconazole)
•9.Patients with the following conditions: asthma, severe cardiovascular disorders (myocardial infarction within 6 week), heart rhythm abnormalities, thyrotoxicosis, uncorrected hypokalaemia, glaucoma, prostate problems, patients with difficulty passing urine, renal failure, TB (current or previous)
•10.Pregnancy
•11.Patients with hypersensitivity to any of the study drugs, lactose allergy

发起方

Royal Marsden Hospital